Trial · NCT01536574
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | Any AE | 58 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Placebo in Parent DB Study, Ropinirole PR in OL Study | Any AE | 56 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | AE Related to Investigational Product (IP) | 33 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Placebo in Parent DB Study, Ropinirole PR in OL Study | AE Related to Investigational Product (IP) | 35 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | Any SAE | 2 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Placebo in Parent DB Study, Ropinirole PR in OL Study | Any SAE | 4 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | SAE Related to Investigational Product (IP) | 0 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Placebo in Parent DB Study, Ropinirole PR in OL Study | SAE Related to Investigational Product (IP) | 1 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | AE Leading to Death | 0 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Placebo in Parent DB Study, Ropinirole PR in OL Study | AE Leading to Death | 0 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | AE Leading to Withdrawal | 4 | Participants | |
Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase) | Placebo in Parent DB Study, Ropinirole PR in OL Study | AE Leading to Withdrawal | 4 | Participants | |
| Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | Dyskinesia | 6 | Participants | |
| Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase | Placebo in Parent DB Study, Ropinirole PR in OL Study | Dyskinesia | 10 | Participants | |
| Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | Dizziness | 5 | Participants | |
| Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase | Placebo in Parent DB Study, Ropinirole PR in OL Study | Dizziness | 3 | Participants | |
| Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | Somnolence | 0 | Participants | |
| Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase | Placebo in Parent DB Study, Ropinirole PR in OL Study | Somnolence | 6 | Participants | |
| Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase | Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study | Akathisia | 0 | Participants | |
| Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase | Placebo in Parent DB Study, Ropinirole PR in OL Study | Akathisia | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01536574/results